AnPac Bio-Medical Science Co., Ltd. (ANPC)

Penny stocks to watch under $1 right now. The post 10 Top Penny Stocks To Buy For Uner $1 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny stocks to watch under $1 right now. The post Good Penny Stocks To Buy Now?

Which penny stocks are you watching right now? The post Cheap Penny Stocks to Buy in September?

The stock price of AnPac Bio-Medical Science (ANPC) increased by 66.01% today. These are some details you should know.

Hot penny stocks to watch but are they a buy now or not? Let's look at the catalysts.

Here's what you need to know about trading penny stocks on May 12th The post What to Know About Buying Penny Stocks on May 12th  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Check these three penny stocks out in April 2022 The post Popular Penny Stocks to Buy in April? 3 to Watch Right Now  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

China penny stocks to watch right now The post Best Penny Stocks To Buy? 5 China Stocks To Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Reddit penny stocks under $1 to watch this week. The post 5 Penny Stocks Under $1 To Buy According To Redditors This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Large Population Screening Study Reached Key Milestone with Over 2,000 Confirmed Cases Large Population Screening Study Reached Key Milestone with Over 2,000 Confirmed Cases

PHILADELPHIA, Oct. 01, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, announced today its unaudited financial results for the six months ended June 30, 2021.

PHILADELPHIA, Sept. 30, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in the United States and China, announced today that it has received a written notification (the "Notification Letter") from the Nasdaq Stock Market LLC (“Nasdaq”) dated September 24, 2021 indicating that the Company is not in compliance with the minimum Market Value of Listed Securities (“MVLS”) set forth in the Nasdaq Rules for continued listing on the Nasdaq Global Market. Nasdaq Listing Rule 5450(b)(2)(A) requires companies to maintain a minimum market value of US$50,000,000 and Listing Rule 5810(c)(3)(C) provides that a failure to meet the market value requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the market value of the Company for the 30 consecutive business days from August 12, 2021 to September 23, 2021, the Company no longer meets the minimum market value requirement. This notification does not impact the listing and trading of the Company's securities at this time.

AnPac Bio-Medical Science (NASDAQ: ANPC) subsidiary AnPac Bio-Medical Science (Lishui) Co. Ltd. has increased its holding in AnPai (Shanghai) Healthcare Management Consultant Co. Ltd.

PHILADELPHIA, Sept. 03, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in the United States and China, today announced that its subsidiary, Anpac Bio-Medical Science (Lishui) Co., Ltd. has increased its holding in one of its subsidiaries AnPai (Shanghai) Healthcare Management Consultant Co., Ltd. (AnPai) with approvals by its audit committee and board of directors. The company has carried out rigorous due diligence including financial and legal audits, as well as appraisals by a qualified appraiser. The company completed the share structure registration amendment with the local Administration Management Bureau in late August 2021.

PHILADELPHIA, Aug. 30, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in the United States and China, today announced that its Philadelphia, PA Clinical Laboratory Improvement Amendments (“CLIA”) certified laboratory has received accreditation from the College of American Pathologists (“CAP”). The U.S. federal government recognizes the CAP Laboratory Accreditation Program, begun in the early 1960s, as being equal-to or more-stringent-than the government's own inspection program. During the CAP accreditation process, designed to ensure the highest standard of care for all laboratory results, inspectors examine the laboratory's records and quality control of the procedures for the preceding two years. CAP inspectors also examine laboratory staff qualifications, equipment, facilities, safety program and records, and overall management.

PHILADELPHIA, Aug. 23, 2021 (GLOBE NEWSWIRE) -- via Investor Wire – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in the United States and China, today announces that the Company filed with China's National Medical Products Administration (NMPA) on Aug. 19, 2021, for registration testing of its class III, multi-cancer detection medical device based on its Cancer Differentiation Analysis Technology (CDA).